Journal Article

High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma

Ng Lawrence Cheng Kiat, Yong Kar Ying, Lim Soon Thye, Goh, Yeow Tee, Chng Wee Joo, de Mel Sanjay, Grigoropoulos Nicholas Francis, Tan Yan Chin, Tan Melinda Si Yun, Chen, Yunxin, Lee, Yuh Shan, Nagarajan Chandramouli, Phipps, Colin, Liu, Xin, Ong Shin Yeu

2021

Overview

The role of central nervous system (CNS) prophylaxis with high-dose methotrexate (HDMTX) in DLBCL is controversial. In this retrospective study, we evaluated the efficacy of prophylactic HDMTX on isolated CNS relapse, concomitant CNS and systemic relapse, systemic relapse, and survival outcomes in 226 patients with newly diagnosed DLBCL and high-risk CNS International Prognostic Index (CNS-IPI) score treated with RCHOP. The three-year risk of isolated CNS relapse was significantly lower in patients who received HDMTX, at 3.1% compared to 14.6% (P = 0.032) in those who did not. However, neither concomitant CNS-systemic relapse rates, systemic relapse rates, nor three-year PFS and OS were significantly different between treatment groups in multivariable analysis. Among propensity score-matched patients (N = 102), HDMTX was also associated with significantly lower isolated CNS relapse rates (HR 0.06, 95% CI 0.004–0.946, P = 0.046). HDMTX was well tolerated with manageable toxicities when given at a dose of 3 g/m2 by day 3 of RCHOP chemotherapy. Using propensity score matching and multivariable regression to yield treatment groups with well-balanced covariates, we showed that prophylactic HDMTX improved isolated CNS relapse rates but did not decrease concomitant CNS-systemic relapse rates, systemic relapse rates, or improve survival outcomes.

• Publisher: Springer Nature B.V
• Subject: Cancer / Chemotherapy / Disease prevention / Drug dosages / Hematology / Lymphoma / Medical prognosis / Nervous system / Patients / Systemic diseases